Literature DB >> 17922025

Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.

B N Dittel1.   

Abstract

The cannabinoid system is now recognized as a regulator of both the nervous and immune systems. Although marijuana has been used for centuries for the treatment of a variety of disorders, its therapeutic mechanisms are only now being understood. The best-studied plant cannabinoid, delta9-tetrahydrocannabinol (THC), produced by Cannabis sativa and found in marijuana, has shown evidence of being immunosuppressive in both in vivo and in vitro. Since THC binds to at least two receptors that are differentially expressed by the immune and nervous systems, it has not been possible to clearly discriminate the biological effects it exerts in the two systems. In addition, endogenous cannabinoids have also been described that bind to both receptors and exert both neuronal and immune modulatory activity. The generation of mice deficient in specific cannabinoid receptors has facilitated studies to discriminate cannabinoid-specific functions. This review focuses on the function of the cannabinoid receptor 2 (CB2), primarily expressed in the immune system, in regulating T cell effector functions associated with autoimmune inflammation in the central nervous system (CNS).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922025      PMCID: PMC2219523          DOI: 10.1038/sj.bjp.0707493

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

Review 1.  Comparative biology of the endocannabinoid system possible role in the immune response.

Authors:  M Salzet; C Breton; T Bisogno; V Di Marzo
Journal:  Eur J Biochem       Date:  2000-08

2.  Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation.

Authors:  S F Lee; C Newton; R Widen; H Friedman; T W Klein
Journal:  Eur J Pharmacol       Date:  2001-07-06       Impact factor: 4.432

3.  Therapeutic action of cannabinoids in a murine model of multiple sclerosis.

Authors:  Angel Arévalo-Martín; José Miguel Vela; Eduardo Molina-Holgado; José Borrell; Carmen Guaza
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 4.  2-Arachidonoylglycerol and the cannabinoid receptors.

Authors:  T Sugiura; K Waku
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

5.  Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells.

Authors:  Michael Yuan; Sylvia M Kiertscher; Qingwen Cheng; Richard Zoumalan; Donald P Tashkin; Michael D Roth
Journal:  J Neuroimmunol       Date:  2002-12       Impact factor: 3.478

6.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.

Authors:  J Ludovic Croxford; Stephen D Miller
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 7.  Nervous system disorders: a global epidemic.

Authors:  Donna C Bergen; Donald Silberberg
Journal:  Arch Neurol       Date:  2002-07

Review 8.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Pharmacol Ther       Date:  2002-08       Impact factor: 12.310

9.  Endocannabinoids control spasticity in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; A Makriyannis; A Khanolkar; L Layward; F Fezza; T Bisogno; V Di Marzo
Journal:  FASEB J       Date:  2000-12-08       Impact factor: 5.191

10.  A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis.

Authors:  E S Huseby; D Liggitt; T Brabb; B Schnabel; C Ohlén; J Goverman
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

View more
  12 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

3.  Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.

Authors:  Sabina Adhikary; Hongbo Li; Joshua Heller; Mario Skarica; Ming Zhang; Doina Ganea; Ronald F Tuma
Journal:  J Neurotrauma       Date:  2011-10-04       Impact factor: 5.269

Review 4.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines.

Authors:  Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2009-02       Impact factor: 8.739

Review 5.  What we know and do not know about the cannabinoid receptor 2 (CB2).

Authors:  Anna Maria Malfitano; Sreemanti Basu; Katarzyna Maresz; Maurizio Bifulco; Bonnie N Dittel
Journal:  Semin Immunol       Date:  2014-05-28       Impact factor: 11.130

Review 6.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Authors:  Roger G Pertwee
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 7.  Neuroimmune interactions and pain: focus on glial-modulating targets.

Authors:  Edgar Alfonso Romero-Sandoval; Ryan J Horvath; Joyce A DeLeo
Journal:  Curr Opin Investig Drugs       Date:  2008-07

8.  Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS.

Authors:  Weimin Kong; Hongbo Li; Ronald F Tuma; Doina Ganea
Journal:  Cell Immunol       Date:  2013-11-14       Impact factor: 4.868

Review 9.  Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.

Authors:  Ming Zhang; Billy R Martin; Martin W Adler; Raj J Razdan; Weimin Kong; Doina Ganea; Ronald F Tuma
Journal:  J Neuroimmune Pharmacol       Date:  2009-03-03       Impact factor: 4.147

10.  Intrinsic up-regulation of 2-AG favors an area specific neuronal survival in different in vitro models of neuronal damage.

Authors:  Sonja Kallendrusch; Constance Hobusch; Angela Ehrlich; Marcin Nowicki; Simone Ziebell; Ingo Bechmann; Gerd Geisslinger; Marco Koch; Faramarz Dehghani
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.